As possible solutions to the opioid crisis have emerged, the question becomes whether the government, pharmaceutical companies or insurers should fund these expensive efforts for wholesale societal repair. Adam H. Fleischer, Chair of BatesCarey’s Opioid Coverage Task Force, sheds light on potential solutions and their funding implications in his latest Law360 expert analysis.